Skip Nav Destination
Issues
1 March 2011
-
Cover Image
Cover Image
VEGF and placental growth factor promote angiogenesis in developing tumors. A novel fusion protein sFLT01 neutralized VEGF and PlGF, and inhibited tumor growth and blood vessel development in preclinical tumor models. Using immunofluorescence, it was found that sFLT01 localized to vascular areas in human A673 Ewing's sarcoma tumors. VEGFR2 protein was also detected throughout the tumor microenvironment. For details, see article by Bagley and colleagues on page 404. - PDF Icon PDF LinkTable of Contents
ISSN 1535-7163
EISSN 1538-8514
Highlights
Spotlight on Molecular Profiling
Reviews
Therapeutic Discovery
Lipoprotein Lipase Links Dietary Fat to Solid Tumor Cell Proliferation
Nancy B. Kuemmerle; Evelien Rysman; Portia S. Lombardo; Alison J. Flanagan; Brea C. Lipe; Wendy A. Wells; Jason R. Pettus; Heather M. Froehlich; Vincent A. Memoli; Peter M. Morganelli; Johannes V. Swinnen; Luika A. Timmerman; Leila Chaychi; Catherine J. Fricano; Burton L. Eisenberg; William B. Coleman; William B. Kinlaw
Preclinical Development
Antagonism of VEGF by Genetically Engineered Dendritic Cells Is Essential to Induce Antitumor Immunity against Malignant Ascites
Masahiko Sugiyama; Yoshihiro Kakeji; Shunichi Tsujitani; Yui Harada; Mitsuho Onimaru; Kumi Yoshida; Sakura Tanaka; Yasunori Emi; Masaru Morita; Yosuke Morodomi; Mamoru Hasegawa; Yoshihiko Maehara; Yoshikazu Yonemitsu
Molecular Medicine in Practice
PIK3CA Mutations in Patients with Advanced Cancers Treated with PI3K/AKT/mTOR Axis Inhibitors
Filip Janku; Apostolia M. Tsimberidou; Ignacio Garrido-Laguna; Xuemei Wang; Rajyalakshmi Luthra; David S. Hong; Aung Naing; Gerald S. Falchook; John W. Moroney; Sarina A. Piha-Paul; Jennifer J. Wheler; Stacy L. Moulder; Siqing Fu; Razelle Kurzrock
Advertisement
NOTICE: This notice serves to inform the reader that, in 2023, AACR received a donation by Pfizer of the rights to royalties from the sale—within the United States—of Bavencio® (avelumab), a pharmaceutical owned by Merck. None of these funds are being, or will be, used to directly support any specific publication or author. If an individual article is published that deals with this particular drug, such article will include standard financial disclosures per AACR journal policy. For more detail regarding AACR’s established policies for authors, please go to https://aacrjournals.org/pages/editorial-policies#coi.
RSS Feeds